| Entry |
| ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Name | Abemaciclib (JAN/USAN); Verzenio (TN) | ||||||||
| Product | VERZENIO (Eli Lilly and Company) | ||||||||
| Formula | C27H32F2N8 | ||||||||
| Exact mass | 506.2718 | ||||||||
| Mol weight | 506.5934 | ||||||||
| Structure |  | ||||||||
| Class | Antineoplastic DG03138 CDK inhibitor Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate | ||||||||
| Remark |
| ||||||||
| Efficacy | Antineoplastic, Cyclin-dependent kinase (CDK) inhibitor | ||||||||
| Disease | Breast cancer (HR positive, HER2 negative) [DS:H00031] | ||||||||
| Comment | Treatment of advanced cancer | ||||||||
| Target | CDK4/6 [HSA:1019 1021] [KO:K02089 K02091] | ||||||||
| Pathway |
| ||||||||
| Metabolism | Enzyme: CYP3A [HSA:1576 1577 1551] | ||||||||
| Interaction | |||||||||
| Brite | Anatomical Therapeutic Chemical (ATC) classification [BR:br08303] L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS L01 ANTINEOPLASTIC AGENTS L01E PROTEIN KINASE INHIBITORS L01EF Cyclin-dependent kinase (CDK) inhibitors L01EF03 Abemaciclib D10688 Abemaciclib (JAN/USAN) <JP/US> USP drug classification [BR:br08302] Antineoplastics Molecular Target Inhibitors Abemaciclib D10688 Abemaciclib (JAN/USAN) Therapeutic category of drugs in Japan [BR:br08301] 4 Agents affecting cellular function 42 Antineoplastics 429 Miscellaneous 4291 Other Antitumors D10688 Abemaciclib (JAN/USAN) Drug groups [BR:br08330] Antineoplastic DG03138 CDK inhibitor D10688 Abemaciclib Metabolizing enzyme substrate DG01633 CYP3A/CYP3A4 substrate D10688 Abemaciclib Drug classes [BR:br08332] Antineoplastic DG03138 CDK inhibitor D10688 Abemaciclib Target-based classification of drugs [BR:br08310] Protein kinases Serine/threonine kinases CMGC group CDK4/6 D10688 Abemaciclib (JAN/USAN) <JP/US> New drug approvals in the USA [br08319.html] New molecular entities and new therapeutic biological products D10688 New drug approvals in Europe [br08329.html] European public assessment reports (EPAR) authorised medicine D10688 New drug approvals in Japan [br08318.html] Drugs with new active ingredients D10688 New drug approvals in the USA, Europe and Japan [br08328.html] Approval dates by FDA, EMA and PMDA D10688 Drug metabolizing enzymes and transporters [br08309.html] Drug metabolizing enzymes D10688 Pharmacogenomic biomarkers [br08341.html] Somatic variations in targeted cancer therapies D10688 | ||||||||
| Other DBs |
| ||||||||
| KCF data | ATOM 37 1 C8x C 18.7600 -14.4900 2 C8y C 18.7600 -15.8900 3 N5x N 19.9724 -16.5900 4 C8x C 21.1849 -15.8900 5 C8y C 21.1849 -14.4900 6 C8x C 19.9724 -13.7900 7 C1x C 23.6097 -15.8900 8 N1y N 23.6097 -14.4900 9 C1b C 22.3973 -13.7900 10 C1x C 24.8222 -16.5900 11 N1y N 26.0346 -15.8900 12 C1x C 26.0346 -14.4900 13 C1x C 24.8222 -13.7900 14 C1b C 27.2470 -16.5900 15 N5x N 16.3351 -14.4900 16 C8y C 16.3351 -15.8900 17 N1b N 17.5476 -16.5900 18 C8x C 15.1227 -13.7900 19 C8y C 13.9103 -14.4900 20 C8y C 13.9103 -15.8900 21 N5x N 15.1227 -16.5900 22 X F 12.6978 -13.7900 23 C8x C 11.4854 -15.8900 24 C8y C 12.6978 -16.5900 25 C8y C 10.2730 -16.5900 26 C8y C 10.2730 -17.9900 27 C8y C 11.4854 -18.6900 28 C8x C 12.6978 -17.9900 29 N5x N 9.2325 -18.9268 30 C8y C 9.8020 -20.2058 31 N4y N 11.1943 -20.0594 32 C1a C 9.2325 -21.4847 33 C1a C 11.4478 -22.4710 34 C1c C 12.0172 -21.1920 35 C1a C 13.4395 -20.9697 36 C1a C 28.4594 -15.8900 37 X F 9.0606 -15.8900 BOND 41 1 1 2 1 2 2 3 2 3 3 4 1 4 4 5 2 5 5 6 1 6 1 6 2 7 7 8 1 8 8 9 1 9 5 9 1 10 7 10 1 11 10 11 1 12 11 12 1 13 12 13 1 14 8 13 1 15 11 14 1 16 15 16 2 17 16 17 1 18 2 17 1 19 15 18 1 20 18 19 2 21 19 20 1 22 20 21 2 23 16 21 1 24 19 22 1 25 23 24 1 26 20 24 1 27 23 25 2 28 25 26 1 29 26 27 2 30 27 28 1 31 24 28 2 32 26 29 1 33 29 30 2 34 30 31 1 35 27 31 1 36 30 32 1 37 33 34 1 38 31 34 1 39 34 35 1 40 14 36 1 41 25 37 1 |